Biologics Drug

Discovery and Development

We focus on innovative biologics and biosimilar programs, addressing unmet
medical needs in oncology, adjuvant chemotherapy, high cholesterol,
autoimmune diseases and ophthalmic drugs.  Advanced technology platforms
have been developed in monoclonal antibody (mAb), Antibody-Drug Conjugate
(ADC), fusion protein and polysaccharides.

Global Business Development

We are actively seeking business opportunities including oncology, autoimmune
diseases, liver diseases, diabetes, cardiovascular diseases and
anti-infectious diseases.

Small molecule-based therapies

  • Prefer development candidates with preliminary efficacy and safety data

Biologics drugs and innovative technology platforms

  • mAbs, bi-specific Abs, probody, ADCs, fusion proteins, therapeutic
    vaccines, nucleic acid drugs and cellular therapy

New Drug Delivery and Formulation Systems

  • Albumin nanoparticles
  • Liposome
  • Microspheres
  • Microcrystalline suspension
  • Lipid micro-emulsion
  • Controlled release formulation